An anti-Gn glycoprotein antibody from a convalescent patient potently 2 inhibits the infection of severe fever with thrombocytopenia syndrome virus. biorxiv.org Oct. 3, 2018; DOI: http://dx.doi.org/10.1101/434530. Read more.
Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. Molecular Cancer Research - AACR. October 1, 2018. DOI: 10.1158/1541-7786.MCR-17-0554. Read more.
Imaging activated T cells predicts response to cancer vaccines. The Journal of Clinical Investigation.Volume 128, Number 6, June 2018. Read more.
Assessment of pharmacology and toxicology of anti-CTLA-4 antibody (ADU-1604) in non-human primates and evaluation of local anti-CTLA-4 application. Aduro Biotech Europe, Oss, The Netherlands; and Aduro Biotech, Berkeley, CA, USA. Poster #1702, 2018. Read more.